These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 36058083)
1. Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification. Baratta F; D'Erasmo L; Bini S; Pastori D; Angelico F; Del Ben M; Arca M; Di Costanzo A Atherosclerosis; 2022 Sep; 357():51-59. PubMed ID: 36058083 [TBL] [Abstract][Full Text] [Related]
2. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Santos RD; Valenti L; Romeo S Atherosclerosis; 2019 Mar; 282():110-120. PubMed ID: 30731283 [TBL] [Abstract][Full Text] [Related]
3. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease. Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250 [TBL] [Abstract][Full Text] [Related]
4. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study. Han E; Chun HS; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Lee BW; Kang ES; Cha BS; Ahn SH; Kim SU J Gastroenterol Hepatol; 2023 Sep; 38(9):1598-1609. PubMed ID: 37321651 [TBL] [Abstract][Full Text] [Related]
5. NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin? Stols-Gonçalves D; Hovingh GK; Nieuwdorp M; Holleboom AG Trends Endocrinol Metab; 2019 Dec; 30(12):891-902. PubMed ID: 31630897 [TBL] [Abstract][Full Text] [Related]
6. MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups. Kim H; Lee CJ; Ahn SH; Lee KS; Lee BK; Baik SJ; Kim SU; Lee JI Dig Dis Sci; 2022 Oct; 67(10):4919-4928. PubMed ID: 35579799 [TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic Fatty Liver Disease as an Emerging Risk Factor and Potential Intervention Target for Atherosclerotic Cardiovascular Diseases. Zhang D; Mi Z; Peng J; Yang T; Han Y; Zhai Y; Song C; Teng X; Sun W; Guo J; Bilonda KP J Cardiovasc Pharmacol; 2023 May; 81(5):327-335. PubMed ID: 36917556 [TBL] [Abstract][Full Text] [Related]